DOCSLIB.ORG

Effect of Ilaprazole on the Healing of Endoscopic Submucosal Dissection-Induced Gastric Ulcer: Randomized-Controlled, Multicenter Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Ilaprazole on the Healing of Endoscopic Submucosal Dissection-Induced Gastric Ulcer: Randomized-Controlled, Multicenter Study Surgical Endoscopy (2019) 33:1376–1385 and Other Interventional Techniques https://doi.org/10.1007/s00464-018-6412-9 Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study Chang Seok Bang1,2 · Woon Geon Shin1,3 · Seung In Seo1 · Min Ho Choi1 · Hyun Joo Jang1 · Se Woo Park1 · Sea Hyub Kae1 · Young Joo Yang1 · Suk Pyo Shin1 · Gwang Ho Baik1 · Hak Yang Kim1 Received: 18 May 2018 / Accepted: 24 August 2018 / Published online: 30 August 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Background The optimal treatment regimen or the duration of treatment for an endoscopic submucosal dissection (ESD)- induced gastric ulcer has not been established. The aim of this study was to assess the efficacy of novel proton-pump inhibitor, ilaprazole, for the treatment of ESD-induced gastric ulcer. Methods This was a prospective, open-label, randomized multicenter study. Between June 2015 and March 2018, a total of 176 patients (178 lesions) who underwent ESD for a gastric neoplasm were randomly allocated to receive the oral proton- pump inhibitor ilaprazole 20 mg or rabeprazole 20 mg daily for 8 weeks. The primary outcome was the ulcer healing rate at 4 and 8 weeks. Results A total of 155 (157 lesions) and 154 patients (156 lesions) were included in the modified intention-to-treat (mITT) and per-protocol analyses, respectively. There was no significant difference in the ulcer healing rate (ilaprazole vs. rabepra- zole, 97.4% vs. 97.0 p = 0.78 at 4 weeks, 100% vs. 100%, p = 0.95 at 8 weeks in the mITT analysis) or stage of ulcer (scar stage, 25.6% vs. 17.7%, p = 0.25 at 4 weeks, 92.3% vs. 88.6%, p = 0.59 at 8 weeks in the mITT analysis) between the treat- ment groups. The quality of ulcer healing was not significantly different between the two groups. No independent predictive factor for higher-quality ulcer healing was found in the multivariate analysis. Conclusions According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artifi- cial gastric ulcers. Most of the ulcers achieved complete healing within 4–8 weeks. Trial registration: ClinicalTrial.gov NCT02638584. Keywords Gastric ulcer · Endoscopic submucosal dissection · Ilaprazole · Rabeprazole · Endoscopy Abbreviations mITT Modified intention-to-treat ESD Endoscopic submucosal dissection PP Per-protocol PPI Proton-pump inhibitor IQR Interquartile range H. pylori Helicobacter pylori SD Standard deviation KGSRS Korean form of Gastrointestinal Symptom Rat- OR Odds ratio ing Scale CI Confidence interval n Number * Woon Geon Shin BMI Body mass index [email protected] 1 Department of Internal Medicine, Hallym University College Endoscopic submucosal dissection (ESD) has been estab- of Medicine, Chuncheon, South Korea lished as a primary treatment option for a specific subset of 2 Institue of New Frontier Research, Hallym University patients with gastric neoplasms who have a negligible risk of College of Medicine, Chuncheon, South Korea lymph node metastasis [1, 2]. With technical advancements, 3 Division of Gastroenterology, Department of Internal treatment outcomes in patients with gastric neoplasms who Medicine, Hallym University Kangdong Sacred Heart Hospital, 150 Seongan-ro, Gangdong-gu, Seoul 05355, meet the criteria for endoscopic resection have reached a South Korea level comparable to those of surgical resection [3, 4]. ESD Vol:.(1234567890)1 3 Surgical Endoscopy (2019) 33:1376–1385 1377 has the advantage of an en bloc resection of neoplastic tissue known hypersensitivity to any component of ilaprazole; and is less invasive than surgery because the stomach is pre- (2) taking a medication contraindicated with experimental served if curative resection is achieved. However, to achieve and concomitant drugs; (3) abnormal levels of laboratory clear resection margins, this procedure inevitably leaves a tests (serum total bilirubin or creatinine > 1.5 times the large and deep ulcer, which can lead to major complica- upper limit of normal and alanine transaminase, aspartate tions. Hemorrhage of the ESD-induced ulcer is immediately transaminase, alkaline phosphatase, and blood urea nitro- treated during the procedure; however, delayed bleeding is gen > 2 times upper limit of normal); (4) history of malig- also a drawback of ESD [1]. Proton-pump inhibitors (PPIs) nancy within 5 years other than gastric cancer; (5) history are the most widely used anti-ulcer medication and are cur- of Zollinger-Ellison syndrome, Barrett’s esophagus, primary rently the standard treatment, not only in patients with pep- esophageal motility abnormality, esophageal strictures, pan- tic ulcers but also in patients with ESD-induced artificial creatitis, malabsorption, severe cardiovascular or pulmonary gastric ulcers. We previously reported that a combination disease; (6) history of major surgery that can affect gastric therapy of oral PPI and rebamipide, a mucosa-protective acid secretion; (7) cannot discontinue the following medi- agent, for 4 weeks is more effective than oral PPI mono- cations during the study period: anticholinergics, motility- therapy in terms of the healing rate and quality of healing of promoting agents, prostaglandin analogs, sucralfate, aspi- ESD-induced gastric ulcers [5]. However, the optimal treat- rin, steroids, and nonsteroidal anti-inflammatory drugs; (8) ment regimen (intravenous vs. oral, continuous infusion vs. uncontrolled organ failure (liver dysfunction or renal dys- intermittent injections, once daily vs. twice daily, etc.) or function); and (9) pregnant and/or breast feeding women. duration of treatment for ESD-induced gastric ulcers has not been established. Study design Ilaprazole (Noltec®; IL-YANG Pharmaceutical Co., Ltd., Seoul, Korea) has a prolonged plasma half-life compared This was a prospective, open-label, randomized multicenter to other available PPIs and is not significantly influenced study. Sample size was calculated by using an α-error < 0.05 by CYP2C19 polymorphisms, which limits the efficacy of and a β-error < 0.2 with a two-tailed significance test. The a PPI [6, 7]. This medication is also known to provide bet- calculated number of lesions required for the study was ter pH control over 24 h without plasma gastrin concen- 70 in each arm, determined by assuming a healing rate of tration elevation compared with esomeprazole [8]. Rabe- 87% over 8 weeks of treatment with a 2nd-generation oral prazole, which is a 2nd-generation PPI like esomeprazole, PPI based on a previous study, a non-inferiority margin of was reported to have a stronger acid suppressing efficacy 15%, and a drop rate of 10% [13]. All patients were given than 1st-generation PPIs [8, 9]. It is also less affected by intravenous injections of pantoprazole 40 mg on the first CYP2C19 polymorphisms, which is more prevalent in East 2 days after ESD. Oral feeding was initiated on the second Asian countries than Western countries [10]. Although there day after performing the 2nd-look endoscopy to check for are theoretical advantages of these drugs, the comparative post-ESD hemorrhage. Patients with bleeding resumed their efficacy of ilaprazole with rabeprazole for the treatment of diet after confirming complete hemostasis. On the third day, ESD-induced artificial gastric ulcers has not been evaluated. the patients who met the inclusion and exclusion criteria Therefore, we assessed the comparative efficacy of ilapra- were randomly assigned to the ilaprazole or the rabeprazole zole and rabeprazole for the treatment of ESD-induced gas- group. A single independent study coordinator prepared the tric ulcers. randomization sequence, which was accomplished by using a block design with a block size of 4. Randomization of the block was conducted using a random-number chart. Methods Beginning on the third day after ESD, the patients in the ilaprazole group were administered ilaprazole 20 mg oral Study population tablets once a day for 56 days, and the patients in the rabe- prazole group were administered rabeprazole 20 mg oral Patients who underwent ESD for the treatment of gastric tablets once a day for 56 days. The enrolled patients under- adenoma or early gastric cancer from June 2015 to March went follow-up endoscopy at 4 weeks and 8 weeks after ESD 2018 at the Hallym University-Affiliated Hospitals, includ- to evaluate the degree and quality of ulcer healing. Adverse ing the Chuncheon, Kangdong, and Dongtan Sacred Heart events and drug compliance were evaluated at 4 weeks and Hospital were enrolled. Inclusion criteria were as follows: 8 weeks. The visit window was 1 week. Helicobacter pylori (1) 19 years of age or older; (2) pathologically diagnosed (H. pylori) infection was evaluated by histopathologic exam- gastric adenoma or cancer that was eligible for ESD [11, ination, rapid urease test (Pronto Dry New®; Medical Instru- 12]; and (3) agreed to participate and voluntarily provided ments Corp., Herford, Germany), and/or the 13C-urea breath informed consent. Exclusion criteria were as follows: (1) test (HeliFinder cap®; MediChems Corp., Seoul, Korea) 1 3 1378 Surgical Endoscopy (2019) 33:1376–1385 before performing the ESD. We defined H. pylori infection ulcer area − ulcer area at 4 or 8 weeks) × 100/initial ulcer as positive when at least one of the tests showed positivity. area]. The maximum diameter and the largest diameter All enrolled patients were asked to complete the modified perpendicular to the maximum diameter of the ulcer were Korean form of the Gastrointestinal Symptom Rating Scale measured using an endoscopic measuring device (M2-3U®; (KGSRS) to evaluate the change in clinical symptoms before Olympus Co., Ltd., Tokyo, Japan). Ulcerated areas were cal- and after performing ESD [14, 15]. KGSRS is a rating scale culated by multiplying these two diameters. The secondary consisting of 15 parameters and is widely used to assess outcomes were change in ulcer stage, quality of ulcer heal- abdominal symptoms in patients with peptic ulcers. ing, change in clinical symptoms, and whether healing was The study protocol adhered to the ethical guidelines delayed after ESD.
Load more

Recommended publications
  • Pyridoxine Hydrochloride Pyrrolnitrin Quetiapine Fumarate
    21822182 Infrared Reference Spectra JP XVII Pyridoxine Hydrochloride Pyrrolnitrin Quetiapine Fumarate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21832183 Quinapril Hydrochloride Quinine Ethyl Carbonate Quinine Sulfate Hydrate The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21842184 Infrared Reference Spectra JP XVII Rabeprazole Sodium Ranitidine Hydrochloride Rebamipide The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) JP XVII Infrared Reference Spectra 21852185 Reserpine Ribavirin Rifampicin The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.) 21862186 Infrared Reference Spectra JP XVII Risperidone Ritodrine Hydrochloride Rokitamycin The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs, General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia.
    [Show full text]
  • A Systematic Review of Proton Pump Inhibitors for the Treatment of Adult Patients with Symptomatic Gastroesophageal Reflux Disease Or Peptic Ulcer Disease
    Title A systematic review of proton pump inhibitors for the treatment of adult patients with symptomatic gastroesophageal reflux disease or peptic ulcer disease. Review Question(s) Requested Requested by PSD 1. What is the comparative effectiveness of different proton pump inhibitors in patients with symptoms of gastroesophageal reflux disease? 2. What is the comparative effectiveness of different proton pump inhibitors in treating peptic (duodenal and gastric) ulcer? 3. What are the comparative safety and adverse events of different proton pump inhibitors in patients being treated for symptoms of gastroesophageal reflux disease and peptic ulcer? 4. Are there subgroups of patients based on demographics, other medications, or comorbidities (including nasogastric tubes and inability to swallow solid oral medication) for which a particular proton pump inhibitor or preparation is more effective or associated with fewer adverse effects? Drug The following five proton pump inhibitors (PPI) drugs will be reviewed 1. Esomeprazole (Nexium® and its generic equivalent) 2. Lansoprazole (Prevacid® and its generic equivalent) 3. Omeprazole* (Losec® and its generic equivalent) 4. Pantoprazole* sodium and magnesium (Pantoloc®, Panto IV and their generic equivalent and Tecta® 5. Rabeprazole* (Pariet® and its generic equivalent) Note: *Omeprazole, Pantoprazole and Rabeprazole have been identified as reference drugs by PSD. Esomeprazole and Lansoprazole will be compared to these three reference drugs. TABLE OF CONTENTS TABLE OF CONTENTS ..........................................................................................................................2
    [Show full text]
  • Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3 S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/07/27/dmd.116.070722.DC1 1521-009X/44/10/1543–1549$25.00 http://dx.doi.org/10.1124/dmd.116.070722 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1543–1549, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3 s Kenji Ikemura, Yugo Hamada, Chinatsu Kaya, Tomoyuki Enokiya, Yuichi Muraki, Hiroki Nakahara, Hajime Fujimoto, Tetsu Kobayashi, Takuya Iwamoto, and Masahiro Okuda Department of Clinical Pharmacy and Biopharmaceutics, Mie University Graduate School of Medicine, Tsu (K.I., Y.H., T.I., M.O.); Department of Pharmacy, Mie University Hospital, Tsu (K.I., T.E., Y.M., T.I., M.O.); Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka (C.K.); Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu (H.N., H.F., T.K.), Mie, Japan Received March 30, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Pemetrexed, a multitargeted antifolate, is eliminated by tubular effect of lansoprazole was much greater than those of other PPIs secretion via human organic anion transporter 3 (hOAT3). Although and the apparent IC50 value of lansoprazole against pemetrexed proton pump inhibitors (PPIs) are frequently used in cancer patients, transport via hOAT3 was 0.57 6 0.17 mM. The inhibitory type of the drug interaction between PPIs and pemetrexed remains to be lansoprazole was competitive. In a retrospective study, multivariate clarified.
    [Show full text]
  • Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: a Randomized, Multicenter, Controlled Trial—STORM STUDY
    Original Article J. Clin. Biochem. Nutr., 40, 148–155, March 2007 Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial—STORM STUDY Soo-Heon Park1,*, Chul-Soo Cho1, Oh-Young Lee2, Jae-Bum Jun2, San-Ren Lin3, Li-Ya Zhou3, Yao-Zong Yuan4, Zhao-Shen Li5, Xiao-Hua Hou6, Hong-Chuan Zhao7, Udom Kachintorn8, Chomsri Kositchaiwat9, and Comson Lertkupinit10 1St. Mary’s Hospital, The Catholic University of Korea, Seoul 150-713, Korea 2Hanyang University Hospital, Hanyang University, Seoul 133-792, Korea 3The Third Hospital, Peking University, Beijing 100083, China 4Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China 5Changhai Hospital, Second Military Medical University, Shanghai 2000433, China 6Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China 7Beijing China-Japan Friendship Hospital, Beijing 100029, China 8Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand 9Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand 10Chonburi Hospital, Chonburi 20000, Thailand Received 10 August, 2006; Accepted 7 November, 2006 Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) have gastrointestinal side effects such as dyspepsia, peptic ulcer, hemorrhage, and perforation. Misoprostol and PPIs have been used to prevent NSAID-induced gastroduodenal injury. Rebamipide increases gastric mucus and stimulates the production of endogenous prostaglandins. The prophylactic effect of rebamipide on NSAID-induced gastrointestinal complications is unknown. The aim of this study was to compare NSAID-induced gastrointestinal complications in rebamipide- and misoprostol-treated groups. Patients were randomized to two groups and took a conventional NSAID plus rebamipide or misoprostol for 12 weeks. Gastric mucosal damage was evaluated by endoscopy at screening and the end of the study.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Multi-Layered Pharmaceutical Composition for Both Intraoral and Oral Administration
    Europäisches Patentamt *EP001260216A1* (19) European Patent Office Office européen des brevets (11) EP 1 260 216 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 9/24, A61K 9/00, 27.11.2002 Bulletin 2002/48 A61K 9/48 (21) Application number: 02007778.0 (22) Date of filing: 06.04.2002 (84) Designated Contracting States: • Midha, Kamal K. AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Hamilton HM 12, Bermuda (US) MC NL PT SE TR • Hirsh, Mark Designated Extension States: Wellesley, MA 2481 (US) AL LT LV MK RO SI • Lo, Whe-Yong Canton, MA 02021 (US) (30) Priority: 15.05.2001 US 858016 (74) Representative: (71) Applicant: Peirce Management, LLC COHAUSZ DAWIDOWICZ HANNIG & PARTNER Wellesley, MA 02481 (US) Schumannstrasse 97-99 40237 Düsseldorf (DE) (72) Inventors: • Hirsh, Jane C. Wellesley, MA 02481 (US) (54) Multi-layered pharmaceutical composition for both intraoral and oral administration (57) New pharmaceutical composition in unit dos- capable of intraoral administration; and age form 1 are disclosed for both intraoral and oral ad- ministration to a mammalian patient, said unit dosage (b) as a second portion 4 located within said first form configured to be placed intraorally of said patient, portion 3, a therapeutically effective amount of at which comprises: least one pharmaceutically active ingredient capa- ble of oral administration and which is releasable (a) as a first portion 3 , at least one discrete outer and orally ingestible by the patient after the outer layer comprising a therapeutically effective amount layer has disintegrated or has dissolved intraorally.
    [Show full text]
  • Comparative Efficacy of Various Anti-Ulcer Medications After Gastric Endoscopic Submucosal Dissection: a Systematic Review and Network Meta-Analysis
    Surgical Endoscopy (2019) 33:1271–1283 and Other Interventional Techniques https://doi.org/10.1007/s00464-018-6409-4 Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis Eun Hye Kim1 · Se Woo Park2 · Eunwoo Nam3 · Jae Gon Lee4 · Chan Hyuk Park4 Received: 4 May 2018 / Accepted: 24 August 2018 / Published online: 30 August 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Background The comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection (ESD) has not been fully evaluated. Recently, vonoprazan, a novel potassium-competitive acid blocker, has also been used in ulcer treatment after ESD. Methods We searched for all relevant randomized controlled trials examining the efficacy of anti-ulcer medications after gastric ESD, published through October 2017. Healing of iatrogenic ulcers was investigated at 4–8 weeks after ESD. A network meta-analysis was performed to calculate the network estimates. Results Twenty-one studies with 2005 patients were included. Concerning the comparative efficacy for ulcer healing at 4 weeks after ESD, no network inconsistency was identified (Cochran’s Q-test, df = 10, P = 0.13; I2 = 34%). A combination therapy of proton-pump inhibitor (PPI) and muco-protective agent was superior to PPI alone [risk ratio (RR) (95% confi- dence interval, CI) 1.69 (1.20–2.39)]. The combination therapy of PPI and muco-protective agents tended to be superior to vonoprazan [RR (95% CI) 1.98 (0.99–3.94)]. There was no difference of ulcer healing effect between PPI and vonoprazan [RR (95% CI) PPI vs.
    [Show full text]
  • Bismuth Salts for Gastrointestinal Issues: a Review of the Clinical Effectiveness and Guidelines DATE
    TITLE: Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines DATE: 24 November 2015 CONTEXT AND POLICY ISSUES Oral bismuth formulations have been used effectively for prophylaxis and treatment of both diarrhea and for treatment of Helicobacter pylori (H. pylori) infection.1,2 Bismuth formulations available without a prescription have been commonly used to treat episodic diarrhea for over a century. Bismuth has also been used to treat ulcers prior to the appreciation of its antimicrobial activity against the then unknown causative micro-organism, H. pylori.1 Episodes of diarrhea are especially common in travelers to resource-poor countries. It is estimated that 30% to 70% of international travelers will develop diarrhea during travels or upon return. Typically diarrhea is self-diagnosed and the causal infectious agent remains unknown. While the condition is frequently self-limiting, treatment can reduce the duration, severity, and inconvenience of diarrhea while travelling. Commonly used treatments include antibiotics, antimotility agents, oral rehydration solutions, and bismuth subsalicylate.2 H. pylori infection is a substantial public health concern as it plays a causative role in the pathogenesis of many gastrointestinal conditions such as gastritis, peptic ulcers, and gastric cancer.3 Current treatment regimens designed to eradicate infection utilize more than one antibiotic simultaneously in a standard triple therapy (STT) consisting of a proton-pump inhibitor (PPI), and two antibiotics.
    [Show full text]
  • Rebamipide Does Not Protect Against Naproxen-Induced Gastric Damage: a Randomized Double-Blind Controlled Trial Thiago Gagliano-Jucá1*, Ronilson A
    Gagliano-Jucá et al. BMC Gastroenterology (2016) 16:58 DOI 10.1186/s12876-016-0472-x RESEARCH ARTICLE Open Access Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial Thiago Gagliano-Jucá1*, Ronilson A. Moreno2, Tiago Zaminelli3, Mauro Napolitano4, Antônio Frederico N. Magalhães5, Aloísio Carvalhaes6, Miriam S. Trevisan5,JohnL.Wallace7 and Gilberto De Nucci3,7,8 Abstract Background: Rebamipide is a gastroprotective agent with promising results against gastric damage induced by non-steroidal anti-inflammatory drugs. The present study evaluated if rebamipide protects against naproxen-induced gastric damage in healthy volunteers. Changes in gastric PGE2 tissue concentration were also evaluated. Methods: After a preliminary endoscopy to rule out previous gastric macroscopic damage, twenty-four healthy volunteers of both sexes were divided into 2 groups. One group received sodium naproxen 550 mg b.i.d. plus placebo for 7 days, while the other group received sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d. At the end of treatment, a new endoscopy was performed. Gastric macroscopic damage was evaluated by the Cryer score and by the modified Lanza score. The primary outcome measure of the trial was the macroscopic damage observed in each treatment group at the end of treatment. Biopsies were collected at both endoscopies for PGE2 quantification and histopathological analysis (secondary outcomes). Tissue PGE2 was quantified by ELISA. The randomization sequence was generated using 3 blocks of 8 subjects each. Volunteers and endoscopists were blind to whether they were receiving rebamipide or placebo. Results: All recruited volunteers completed the trial.
    [Show full text]
  • New and Future Drug Development for Gastroesophageal Reflux Disease
    J Neurogastroenterol Motil, Vol. 20 No. 1 January, 2014 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm.2014.20.1.6 JNM Journal of Neurogastroenterology and Motility Review New and Future Drug Development for Gastroesophageal Reflux Disease Carla Maradey-Romero and Ronnie Fass* The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug devel- opment for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)’s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist’s, extended release PPI’s, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies. (J Neurogastroenterol Motil 2014;20:6-16) Key Words Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors Most patients with GERD fall into 1 of 3 categories: non- erosive reflux disease (NERD), erosive esophagitis (EE), and Introduction Barrett’s esophagus (BE). The 2 main phenotypes of GERD, Gastroesophageal reflux disease (GERD) is a common con- NERD and EE, appear to have different pathophysiological and dition that develops when reflux of stomach contents cause trou- clinical characteristics.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]